摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(diethoxymethyl)-5,5-dimethylcyclohexan-1-one

中文名称
——
中文别名
——
英文名称
2-(diethoxymethyl)-5,5-dimethylcyclohexan-1-one
英文别名
2-(Diethoxymethyl)-5,5-dimethylcyclohexan-1-one
2-(diethoxymethyl)-5,5-dimethylcyclohexan-1-one化学式
CAS
——
化学式
C13H24O3
mdl
——
分子量
228.332
InChiKey
SQQBMROHOYUNEU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-(diethoxymethyl)-5,5-dimethylcyclohexan-1-one3-碘-1-(三氟甲基)双环[1.1.1]戊烷仲丁基锂 作用下, 以 四氢呋喃环己烷 为溶剂, 反应 4.5h, 生成 2-(diethoxymethyl)-5,5-dimethyl-1-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)cyclohexanol
    参考文献:
    名称:
    [EN] BENZAMIDE COMPOUNDS
    [FR] COMPOSÉS BENZAMIDE
    摘要:
    本文提供了化学式(I)的化合物。这些化合物以及其药用盐和组合物可用于治疗疾病或病况,包括由细胞过度增殖引起的病况,如癌症和肿瘤,以及病毒感染如HIV。
    公开号:
    WO2019139902A1
  • 作为产物:
    描述:
    3,3-二甲基环己酮原甲酸三乙酯三氟化硼乙醚N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以83%的产率得到2-(diethoxymethyl)-5,5-dimethylcyclohexan-1-one
    参考文献:
    名称:
    [EN] BCL-2 PROTEIN INHIBITORS
    [FR] INHIBITEURS DE PROTÉINE BCL-2
    摘要:
    描述了各种Bcl-2蛋白抑制剂,以及使用它们治疗过度细胞增殖的疾病的方法,如癌症和肿瘤。在各种实施例中,Bcl-2蛋白抑制剂是以下式(I)的化合物或药用可接受盐,其中式(I)中的变量在此处定义。
    公开号:
    WO2021007307A1
点击查看最新优质反应信息

文献信息

  • [EN] BCL-2 PROTEIN INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE BCL-2
    申请人:RECURIUM IP HOLDINGS LLC
    公开号:WO2021007307A1
    公开(公告)日:2021-01-14
    Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein.
    描述了各种Bcl-2蛋白抑制剂,以及使用它们治疗过度细胞增殖的疾病的方法,如癌症和肿瘤。在各种实施例中,Bcl-2蛋白抑制剂是以下式(I)的化合物或药用可接受盐,其中式(I)中的变量在此处定义。
  • [EN] BENZAMIDE COMPOUNDS<br/>[FR] COMPOSÉS BENZAMIDE
    申请人:ZENO ROYALTIES & MILESTONES LLC
    公开号:WO2019139902A1
    公开(公告)日:2019-07-18
    Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    本文提供了化学式(I)的化合物。这些化合物以及其药用盐和组合物可用于治疗疾病或病况,包括由细胞过度增殖引起的病况,如癌症和肿瘤,以及病毒感染如HIV。
  • Benzamide compounds
    申请人:Recurium IP Holdings, LLC
    公开号:US11318134B2
    公开(公告)日:2022-05-03
    Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    本研究提供了具有式(I)的化合物。此类化合物、及其药学上可接受的盐和组合物,可用于治疗各种疾病或病症,包括以细胞过度增殖为特征的疾病,如癌症和肿瘤,以及病毒性感染,如HIV。
  • BENZAMIDE COMPOUNDS
    申请人:Recurium IP Holdings, LLC
    公开号:US20200339605A1
    公开(公告)日:2020-10-29
    Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
  • NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR
    申请人:Recurium IP Holdings, LLC
    公开号:US20220273666A1
    公开(公告)日:2022-09-01
    Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.
查看更多